

# Steve Stranne

SHAREHOLDER

Washington, D.C. | 202.626.8313

[sstranne@polsinelli.com](mailto:sstranne@polsinelli.com)



Steve Stranne is a physician and lawyer who advises companies, health care organizations, professional societies, start-ups and patient advocacy organizations when Medicare coverage, coding or reimbursement decisions affect payment and access for medical technologies and services. He represents clients in reimbursement, coverage, coding, health care policy and patient access matters involving federal and state agencies.

Steve's work focuses on the clinical, economic and policy issues that shape how medical technologies and services are covered, coded, paid for and made available to patients. He interprets and shapes clinical literature, legislation, regulations and coverage policies, and presents clinical and scientific issues to policymakers and decision-makers within federal and state agencies. He works with clients to understand the interplay between clinical, economic and political stakeholders and to develop arguments tailored to each audience.

Steve advocates for clients before the U.S. Congress, the Centers for Medicare & Medicaid Services (CMS), Medicare Administrative Contractors, including DME MACs, the Food and Drug Administration (FDA), and other agencies within the U.S. Department of Health and Human Services (HHS). His work includes developing policies, legislative language, comments, position papers and advocacy strategies affecting regulatory and reimbursement frameworks.

He works with organizational clients to identify legislative and regulatory objectives aligned with their mission or business goals, build internal consensus when necessary and coordinate across legal and policy functions, including patent, copyright, FDA, corporate and health care compliance considerations.

## Education

- Harvard Law School (J.D., 1994)
- Duke University Medical School (M.D., 1990)
- Duke University (B.S.E., 1986)
  - Mechanical Engineering

## Bar Admissions

## Capabilities

- Health Care
- Public Policy
- Public Policy - Health Care
- Government Investigations
- Health Care Reimbursement

- District of Columbia

## Memberships

- American Health Lawyers Association, Member

## Recognition

- Recognized by *LMG Life Sciences* for Medical Device and Health Care Pricing and Reimbursement, 2012-2025
- Selected for inclusion in *Best Lawyers in America*® for Health Care Law, 2025-2026

# Matters

---

- Coverage, Coding and Reimbursement, including establishing and revising Medicare's local coverage determinations (LCDs), Medicare's national coverage determinations (NCDs), policies involving Medicare's physician fee schedule (MPFS), hospital outpatient prospective payment system (hospital OPPOS), transitional pass-through (TPT) submissions, new technology add-on payment (NTAP) submissions and coding requests before the HCPCS Workgroup (relating to Level II HCPCS codes).
- Congressional and Federal Agency Lobbying, including developing draft policies, comments, position papers, legislative language and implementing advocacy strategies before the Centers for Medicare & Medicaid Services (CMS), Food and Drug Administration (FDA), U.S. Congress, Medicare Administrative Contractors (MACs, including DME MACs), HCPCS Workgroup (for securing new and revised HCPCS codes), American Medical Association's CPT Panel (for securing new and revised CPT codes) and Medicare's Pricing Data Analysis and Coding (PDAC) Contractor.
- CPT Coding, including work with manufacturers, professional societies and the American Medical Association's CPT Panel on the establishment, revision and valuation of CPT codes.
- Healthcare Legal Issues, including contracting and compliance with federal and state laws concerning fraud, abuse and waste.
- Issues involving a wide range of medical technologies, services and innovations, including medical devices, digital health technology, artificial intelligence, radiation oncology technology, brachytherapy sources, radiopharmaceuticals, branded and generic pharmaceuticals, biologics and biosimilars, ophthalmology procedures, otolaryngology technologies, cardiovascular interventions, orthotics, durable medical equipment (DME), wound care products, skin substitutes, orthopedic implants and other technologies.

# Publications

---

May 8, 2026

## **Beyond the Pump: The Iran War's Adverse Impact on U.S. Health Care**

April 29, 2026

### **Election Year Politics and Policy at CMMI: What Stakeholders Can Expect**

April 27, 2026

### **Radiation Oncology Community Seeking Relief from an Emerging Crisis under 2026 Changes to Medicare Coding and Reimbursement**

April 15, 2026

### **Budget Reconciliation and Health Policy: Understanding the Legislative Process and Where Congress May Go Next**

April 10, 2026

### **CMS proposes closing optional reimbursement pathways for new innovative medical devices and antimicrobials**

April 7, 2026

### **The Politics of AI Regulation: Federal Government v. the States**

March 27, 2026

### **Action Alert: CMS Accepting Letters of Intent for New Funding Model to Pilot Lifestyle Interventions Within Original Medicare – Letters Due by April 10**

March 16, 2026

### **Hospitals and Health Care Providers Brought before Congress to Testify on Health Care Costs**

March 5, 2026

### **Off and Running: The U.S. House of Representatives Kicks Off the Fiscal Year 2027 Appropriations Cycle**

March 13, 2024

### **Regulatory, Reimbursement, and Government Affairs Issues for Life Sciences Companies**

*Panel Speaker, A Joint Event Sponsored by the Swedish-American Chamber of Commerce and Swecare, House of Sweden*

December 2, 2023

### **Legal Issues related to Coverage of Innovative Technologies**

*Speaker, 20th Annual Global Cardiovascular Clinical Trialist Forum*

November 30, 2023

### **Ensuring Continuity of Patient Care: Upholding Interchangeability Status for Biosimilars**

*Panel Moderator, Alliance for Safe Biologic Medicines and the Generics and Biosimilars Initiative*

July 26, 2023

### **Medicare Drug Price Negotiations: Impact on Healthcare Development and Patient Access to Medicines**

*Panel Moderator, Alliance for Safe Biologic Medicines and the Generics and Biosimilars Initiative*

2020

**Oncology and Health Care Policy**

*Chapter Co-Author, Chapter 20 in Abeloff's Clinical Oncology, Sixth Edition, Elsevier, Inc.  
2020*

June 3, 2013

**The Affordable Care Act: Legislative Update and What to Expect in Oncology**

*Speaker, 2013 Annual Meeting of the American Society of Clinical Oncology*